THE Oxford/AstraZeneca vaccine has been quite the political football over the past few months, particularly in the EU. There have been concerns about its efficacy, its safety and its availability, which appear to have lowered trust.
As one of the leading COVID-19 vaccines available, it’s vital that it is supported by the general public. The latest phase 3 trial data for the vaccine, coming from the US, could potentially boost its profile by helping to assuage some prior efficacy and safety concerns. But, as seems to be the way with this vaccine, these results themselves have now been called into question.
This US trial involved over 32,000 people, with over 21,000 receiving at least one dose of the vaccine. Preliminary findings – which are yet to be peer reviewed – suggest that when given four weeks apart, two doses show 79% efficacy at preventing symptomatic COVID-19 and 100% efficacy at
You’ve reached your free article limit
Subscribe to enjoy unlimited access to trusted journalism. Cancel anytime.
Subscribe nowNeed help? molokom@insidepolitic.co.za
